Clinical Trials in Houston

Showing 2521-2540 of 8,625 trials

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

NCT04761198

This is an open-label, phase 1b/2, multicenter study designed to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of etigilimab in combination with nivolumab in participants with locally advanced or metastatic solid tumors. Participants will be assigned to receive etigilimab (every 2 weeks) in combination with nivolumab (240 milligrams \[mg\] every 2 weeks).

Solid Tumor, AdultAdvanced Solid TumorMetastatic Solid Tumor

Mereo BioPharma76 participantsStarted Mar 2021

Phoenix, Arizona, United States • Greenbrae, California, United States • Los Angeles, California, United States +13 more locations

COMPLETEDPhase 1/2< 1 mile

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

NCT02098343

The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alone, in patients with platinum sensitive recurrent high grade serous ovarian cancer (HGSOC) with mutated p53. In addition, the study aims to assess the safety profile of the combined APR-246 and carboplatin/PLD chemotherapy regimen compared with carboplatin/PLD chemotherapy regimen alone, to evaluate potential biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial will enroll up to a maximum of 400 patients.

Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53

Aprea Therapeutics247 participantsStarted Mar 2014

Los Angeles, California, United States • Chicago, Illinois, United States • Boston, Massachusetts, United States +52 more locations

A Study of Etigilimab and Nivolumab in Participants With Locally Advanced or Metastatic Tumors

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246

Find Trials by Condition in Houston

Mesenchymal Stromal Cells in Living Donor Kidney Transplantation

Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol

An Innovative Platform for Objective Monitoring of Instrumental Activities of Daily Living

Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma

SNV1521 in Participants with Advanced Solid Tumors

Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis

Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines

DUET Study: A Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy and in Combination With TERN-101 in Noncirrhotic Adults With Presumed Non-Alcoholic Steatohepatitis

The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B

Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population

Extension Study for 43USSA1705

WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors

Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)

A Study of LY3561774 in Participants With Mixed Dyslipidemia

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Infant Mortality Reduction by the Mass Administration of Azithromycin